- Home
- WWW vs PHAT Comparison
WWW vs PHAT Comparison
Compare WWW & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWW
- PHAT
- Stock Information
- Founded
- WWW 1883
- PHAT 2018
- Country
- WWW United States
- PHAT United States
- Employees
- WWW N/A
- PHAT N/A
- Industry
- WWW Shoe Manufacturing
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- WWW Consumer Discretionary
- PHAT Health Care
- Exchange
- WWW Nasdaq
- PHAT Nasdaq
- Market Cap
- WWW 1.3B
- PHAT 1.2B
- IPO Year
- WWW N/A
- PHAT 2019
- Fundamental
- Price
- WWW $21.79
- PHAT $8.78
- Analyst Decision
- WWW Buy
- PHAT Strong Buy
- Analyst Count
- WWW 8
- PHAT 4
- Target Price
- WWW $16.38
- PHAT $22.50
- AVG Volume (30 Days)
- WWW 1.3M
- PHAT 1.9M
- Earning Date
- WWW 11-07-2024
- PHAT 11-07-2024
- Dividend Yield
- WWW 1.84%
- PHAT N/A
- EPS Growth
- WWW N/A
- PHAT N/A
- EPS
- WWW N/A
- PHAT N/A
- Revenue
- WWW $1,787,000,000.00
- PHAT $26,270,000.00
- Revenue This Year
- WWW N/A
- PHAT $6,714.96
- Revenue Next Year
- WWW $6.11
- PHAT $293.69
- P/E Ratio
- WWW N/A
- PHAT N/A
- Revenue Growth
- WWW N/A
- PHAT N/A
- 52 Week Low
- WWW $7.58
- PHAT $6.07
- 52 Week High
- WWW $22.86
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- WWW 73.59
- PHAT 23.73
- Support Level
- WWW $15.22
- PHAT $8.91
- Resistance Level
- WWW $22.86
- PHAT $19.05
- Average True Range (ATR)
- WWW 1.00
- PHAT 1.74
- MACD
- WWW 0.55
- PHAT -1.05
- Stochastic Oscillator
- WWW 85.99
- PHAT 2.19
About WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Lifestyle Group and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.